Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Croma-Pharma Strengthens its Innovative Leadership in the Field of Functional Dermatology by Securing the Exclusive Distribution Rights of UNIVERSKIN, the Most Innovative Personalized Skincare Concept for 11 Important Markets


News provided by

Croma-Pharma GmbH

20 Dec, 2016, 07:33 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Dr Charalampos Arampatzis (CEO UNIVERSKIN SAS) , left and Mag. Andreas Prinz (CEO and Co-Owner Croma-Pharma) signing the agreement (PRNewsFoto/Croma-Pharma GmbH)
This image opens in the lightbox
the packshot of the UNIVERSKIN Primum Serum magistrale (PRNewsFoto/Croma-Pharma GmbH)
This image opens in the lightbox
a UNIVERSKIN Display Shelf with all active ingredients (PRNewsFoto/Croma-Pharma GmbH)
This image opens in the lightbox
the UNIVERSIN machine that mixes the individual formula for each patient (PRNewsFoto/Croma-Pharma GmbH)

VIENNA, December 20, 2016 /PRNewswire/ --

UNIVERSKIN - is a a unique, science-based and physician dispensed bespoke skincare, bridging skincare and functional dermatology. UNIVERSKIN personalized skincare is successfully used by dermatologists, plastic surgeons and aesthetic practitioners in 23 countries worldwide.  

With the aim of further expanding its business activities in the area of dermatological treatments, Austria´s Croma-Pharma GmbH signed a comprehensive licensing and distribution agreement with UNIVERSKIN SAS of France. According to many industry experts, UNIVERSKIN is the most innovative, personalized skincare concept available on the market today. UNIVERSKIN is already highly successfully used by more than 500 dermatologists in France and by dermatologists in 23 countries worldwide.

     (Photo: http://mma.prnewswire.com/media/450867/Photo_1_Arampatzis_Prinz.jpg )

     (Photo: http://mma.prnewswire.com/media/450882/universkin_primum.jpg )

     (Photo: http://mma.prnewswire.com/media/450880/Universkin_1.jpg )
     (Photo: http://mma.prnewswire.com/media/450881/Universkin_3.jpg )

The cooperation was concluded for at least 8 years. The exclusive licensing and distribution rights for all UNIVERSKIN products refer to European countries, namely Germany, Austria, France, Poland, Spain, Portugal, the Netherlands and overseas territories such as Australia, Canada and Brazil. For the licenses and distribution rights Croma-Pharma paid an undisclosed amount in a multimillion Euro range. The Agreement shall enter into force on January 1st 2017.

Under its premium brand Princess®, which is exclusively available through dermatologists and pharmacies, Croma-Pharma offers a comprehensive range of products in the field of non-invasive and minimally-invasive aesthetic medicine. The portfolio includes products based on Hyaluronic Acid like intradermal fillers, lifting threads, face masks, serums and the True Hyaluron series. Currently, extensive studies are being conducted in Europe and the USA for the approval of Croma´s new Botulinum Neurotoxin product, which is expected to be approved in 2019. For doctors, Croma offers all relevant dermatological treatments from one single source in the acclaimed quality "Made in Austria" ("one-stop-shop"). The aesthetic portfolio of the Princess® product line is developed and manufactured by Croma-Pharma GmbH at the company´s headquarters in Leobendorf near Vienna, Austria.

The expert combination of Hyaluronic Acid fillers, lifting threads, Botulinum Neurotoxins and state-of-the-art skincare products provide bespoke and lasting results in the minimally-invasive medical anti-aging approach.

Dr. Charalampos Arampatzis, CEO and co-owner of UNIVERSKIN SAS: "Thanks to this promising collaboration with Croma-Pharma, we are enhancing our sales structure in important markets and significantly improve UNIVERSKINs commercial activity through the recognized expertise of the innovation-driven family-owned company Croma-Pharma."

Mag. Pharm. Andreas Prinz, CEO and co-owner of Croma-Pharma GmbH: "With UNIVERSKIN, we are able to implement the most innovative concept in the field of personalized skincare and a unique medical education system into our portfolio. Doing so, Croma-Pharma underlines its leading position as an innovator in the field of non-invasive and minimally invasive aesthetic medicine. "

About UNIVERSKIN SAS:   

UNIVERSKIN is a pioneer private owned dermatology company, established in 2006 and based in Sophia Antipolis, France. The founding and management team of UNIVERSKIN is comprised of dermatologists, plastic surgeons, pharmacists, biologists, chemists and anatomo-pathologists.

UNIVERSKIN invests massively in research and development to revolutionize skincare and empower doctors to think skin rather than product: back to simplicity for the doctor, more efficacy and a better tolerance for the user.  UNIVERSKIN brings a medical logic in skincare: skin medical analysis conducted by trained physicians, choice of active ingredients, concentration, application duration and then monitoring. For the first time, the doctor can design a minimalist, clinically evidenced skincare delivering real results with only one product.

To build each patients formula, a skin medical analysis is conducted by trained physicians, enabling the selection of the relevant active ingredients out of 19 active ingredients available, developed and made in France after 8 years of research. The doctor will choose the actives and concentration, patients will choose the texture. Up to 1159 potential formulas are possible, in 57 different concentrations. In a preparation time of less than two minutes - the skincare formula will be mixed under the doctor´s control, in front of the patient. It will be fine-tuned over time to match patients lifestyle, age, skin condition, seasonal and environmental aggressions.

About Croma-Pharma GmbH:
Founded in 1976, Croma-Pharma is a globally active, family-owned pharmaceutical company based in Leobendorf, Austria. Croma-Pharma is one of the world's most innovative companies in the growth market of minimally-invasive aesthetic medicine (MIAM).
Under its premium brand Princess® Croma offers facial masks, serums, intradermal-fillers, and lifting threads. These high-quality products are distributed exclusively by doctors and pharmacies. With the production of 6 million pre-filled syringes annually and more than 150 million syringes since its inception, Croma-Pharma is a leading producer of Hyaluronic Acid based products. The success is based on research and development at the company-headquarters in Leobendorf, Austria. Croma´s Management Board has a clear vision for high-quality technologies and courageously seizes opportunities for in-licensing of or acquisitions of complementing companies. Croma-Pharma currently employs about 310 people and operates 11 subsidiaries. Through distribution partnerships, products are marketed in more than 70 countries. Croma-Pharma is an award winning company and celebrated its 40th anniversary in 2016.

For more information about Croma-Pharma, please visit: http://www.croma.at 

Photocredits: Croma/Feelimage Matern   

Photo1:  Dr. Charalampos Arampatzis, Mag. Andreas Prinz, signing

Photocredits:   UNIVERSKIN   

Universkin 1

Universkin 3

Universkin 4

Universkin Primum

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.